Ondansetron Hydrochloride Articles
US FDA warns of heart rhythm problems with GSK’s anti-nausea drug Zofran
16 September 2011
Stock Commentary - New York week to April 13, 2009
16 April 2009
Strativa submits NDA for generic Zofran ODT
15 April 2009
Drug identified to treat opioid addiction
23 February 2009
Actavis launches generic ondansetron in USA
9 July 2007
Teva's ondansetron ANDA approved
2 July 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Mylan gains tentative US OK for generic ondansetron
5 March 2007
Final FDA approval for Mylan's ondansetron
7 February 2007
Dr Reddy's sees $350M sales in 4th-qtr 2006
5 February 2007
Dr Reddy's sees $350M sales in 4th-qtr 2006
5 February 2007
Abraxis launches generic ondansetron injection in USA
8 January 2007
FDA approves first generic ondansetron
8 January 2007
US FDA clears Teva's generic of GSK's Zofran
4 December 2006
Hana Biosci's loss for 2005 deepens to $10M
27 March 2006
Hana reveals progress with ondansetron oral spray
20 March 2006
Positive results for SCOLR's ondansetron CR
27 February 2006
Par gets tentative FDA appro for generic Zofran
27 June 2005
FDA approves GSK's sNDA for Zofran
4 April 2005
Rival to GSK's Zofran enters trials
21 February 2005
Rival to GSK's Zofran enters trials
21 February 2005
Pfizer and GSK drug anti-counterfeiting moves
22 November 2004
GSK prevails in Teva Zofran patent dispute
30 August 2004
Par Pharma buys Kali Labs in $135M deal
21 June 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
MGI Pharma/Helsinn's Aloxi gets US approval
4 August 2003
Stock Commentary - Europe
19 May 2003
GSK wins protection for Ceftin antibiotic
12 May 2003
FDA backs Merck & Co's Emend before panel meeting
10 March 2003
Pfizer takes on India's Ranbaxy over Lipitor
3 March 2003
NY claims of Rx overcharging could lead to industry-wide probe
24 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
MGI to file nausea drug after FDA meeting
13 May 2002
Cipla signs deal with IVAX affiliate
5 September 2001
Dr Reddy to seek approval for generic Zofran in USA
30 August 2001
Glaxo Wellcome/SmithKline Beecham merger still dogged by FTC demands
16 November 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Polish Cancer Drug Price Subsidies End
22 April 1998
Anzemet Launched For PONV In USA
26 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
HMR's Anzemet "Approvable" In USA
17 March 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
HMR Files NDA for Dolasetron
22 April 1996
Zantac Sales Slide 4% At Glaxo Wellcome
11 March 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Glaxo Wellcome Reveals Integration Effects
11 September 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Anderson Center Formulary
31 October 1994
Glaxo's Pipeline Update As Expected
19 September 1994
Competition and Acquisition Pressure Hits Glaxo
19 September 1994
Poor Prospects For Zofran In Face Of Cost Constraints
8 August 1994
1ST HEAD-TO-HEAD KYTRIL/ZOFRAN STUDY
11 July 1994
NEGATIVE VIEWS ON GLAXO
27 June 1994
NIPPON GLAXO LAUNCHES ZOFRAN IN JAPAN
16 May 1994
ZOFRAN LAUNCHED IN JAPAN
25 April 1994
CHEAPER KYTRIL LAUNCHED IN USA
11 April 1994
SERTONE LAUNCH
28 February 1994
GLAXO CONSIDERS OPTIONS FOR USA
28 February 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
COSTS OF "CHEAP" PRESCRIBING, BY ABPI
21 February 1994
GLAXO SEES 25% INTERIM TRADING PROFIT RISE
21 February 1994
ZANTAC EFFECTIVE IN ULCER HEMORRHAGE
14 February 1994
GLAXO'S ZOFRAN APPROVED IN JAPAN
24 January 1994
JAPAN NEWS IN BRIEF
10 January 1994
SANKYO-DEVELOPED DRUGS SPUR GROWTH
10 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
DIVERSIFICATION NOT THE PATH FOR GLAXO
13 December 1993
GLAXO REAFFIRMS COMMITMENT TO R&D
6 December 1993
GLAXO'S DEFENDS ONDANSETRON ROLE
29 November 1993
BRIBERY AND RIVALRY IN PHARMA SECTOR
22 November 1993
STUDY SHOWS PATIENTS PREFER GRANISETRON
22 November 1993
EUROPEAN STOCK COMMENT
22 November 1993
GLAXO RESULTS PLEASE, BUT CONCERNS PERSIST
20 September 1993
STRONG PERFORMANCE FROM GLAXO, AND ZANTAC
13 September 1993
EUROPEAN STOCK COMMENT
6 September 1993
US ZOFRAN APPROVAL LIFTS GLAXO SHARES
23 August 1993
SCHERER AND GLAXO PACT ON ZOFRAN
5 July 1993
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
ORAL ZOFRAN LAUNCHED IN USA
3 May 1993
GLAXO COMPROMISES OVER ONDANSETRON PATENT
26 April 1993
ZOFRAN STUDY RESULTS
26 April 1993
DOUBLE TROUBLE FOR SMITHKLINE BEECHAM
22 March 1993
SETBACKS COULD HIT GROWTH AT SK BEECHAM?
22 March 1993
GLAXO INTERIM PROFITS UP 16%
22 February 1993
GLAXO'S SINGAPORE PLANT SET FOR 1994
15 February 1993
ANALYST TIPS GLAXO FOR CONTINUED SUCCESS
15 February 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
